PubMed Health⌕ Search

PubMed · 16504448

Analysis of 'SHUANGDAN' granules by high-performance liquid chromatography-diode array detection-electrospray ionization tandem mass spectrometry.

Abstract

An HPLC-DAD-ESI-MSn method was developed for simultaneous analysis of the chemical constituents in 'SHUANGDAN' granules, a newly developed drug widely used for treating cardiovascular disease. The chromatographic separation were performed on a Zorbax Stable Bond C18 column (4.6 mmx250 mm, 5 microm) with water with 0.5% acetic acid (A) and acetonitrile (B) as mobile phase. According to the characteristic UV absorption profile, the information of molecular weight and structure provided by ESI-MSn, 29 constituents which attributed to Radix Salviae Miltiorrhizae and Cortex Moutan, respectively, were detected and 28 constituents including 14 phenolic acids, 6 diterpenoid quinones, 6 monoterpenoids and 2 other components were identified, while some isomers were distinguished based on the MSn spectra. This method was rapid and reliable for identification of constituents in complex chemical system, 'SHUANGDAN' granules, and the newly fragmentation patterns proposed could be extended to the compounds elucidation with similar framework.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Qing He, Xing-Jiang Hu, Yi-Yu Cheng. 2006-02-28. Analysis of 'SHUANGDAN' granules by high-performance liquid chromatography-diode array detection-electrospray ionization tandem mass spectrometry.. https://doi.org/10.1016/j.jpba.2006.01.010

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiovascular therapy and pharmacogenetics in 2007.

John Carlquist received a PhD from the Department of Cellular Viral and Molecular Biology at the University of Utah School of Medicine (UT, USA) with research emphasis in molecular immunology. After completion of his training, he received a faculty appointment in the Department of Internal Medicine, University of Utah, where he became interested in immune mechanisms in cardiovascular disease. He developed an interest in genetics through studies of human leukocyte antigen (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart disease. He began the Molecular Diagnostics Laboratory for Intermountain Healthcare and continues to serve as Technical Director; he also directs the Intermountain Heart Study Molecular and Genetic Research Laboratory. Current research interests include the genetics of lipid metabolism as related to coronary heart disease and the genetic factors influencing drug treatment outcomes.

Cardiovascular Agents↗

Ensuring that patients receive full cardiac pharmacotherapy services: a pharmacist's call to arms.

While clinical trials have proven that use of certain cardiovascular drugs improves morbidity and mortality, these drugs are not widely used, they are by and large prescribed in suboptimal doses, and their benefit is further diminished by nonadherence. Pharmacists have the ability to improve the survival of patients with cardiovascular risks. This can only be accomplished through the efforts of the individual pharmacist and the further development of health-system management services. Pharmacists need to leverage their access to patients, their large patient base, and their knowledge of refill dates to improve patient care. Support and development of more pharmacist-directed anticoagulation, hyperlipidemia, and hypertension clinics are also needed.

Cardiovascular Agents↗